Pharma Pioneer

First Patient Receives Gedatolisib in Phase 1b/2 Trial for mCRPC Treatment

22 May 2024
2 min read

Biotechnology firm Celcuity Inc., listed on Nasdaq as CELC, has initiated a Phase 1b/2 clinical trial, known as CELC-G-201, to test the efficacy and safety of gedatolisib combined with Nubeqa® (darolutamide) for metastatic castration-resistant prostate cancer (mCRPC) patients. Gedatolisib is a targeted therapy that inhibits specific PI3K isoforms and mTORC1/2, addressing an unmet need for patients resistant to current androgen receptor inhibitors.
Dr. Igor Gorbatchevsky, Celcuity's Chief Medical Officer, expressed enthusiasm about the trial's potential to offer a novel treatment option. The study is led by Professor Karim Fizazi, who highlights the scientific rationale behind combining PAM inhibitors with next-generation androgen receptor therapies. Celcuity has partnered with Bayer AG, which is supplying Nubeqa® for the trial without charge.
The trial aims to enroll 54 mCRPC patients who have seen disease progression after treatment with an androgen receptor inhibitor. It consists of two phases: Phase 1b, which will assess the safety and determine the optimal dose of gedatolisib, and Phase 2, which will evaluate the radiographic progression-free survival of patients at six months.
Celcuity is dedicated to developing targeted therapies for various solid tumors, with gedatolisib as its lead candidate. The company is also conducting the Phase 3 VIKTORIA-1 trial for HR+/HER2- advanced breast cancer. Celcuity's CELsignia diagnostic platform helps identify patients likely to benefit from targeted therapies. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Elevation Oncology Initiates Global Expansion of EO-3021 Phase 1 Trial with First Japanese Patient Dosing
Pharma Pioneer
2 min read
Elevation Oncology Initiates Global Expansion of EO-3021 Phase 1 Trial with First Japanese Patient Dosing
22 May 2024
Elevation Oncology, a company listed on the Nasdaq (ELEV), is advancing its Phase 1 clinical trial for EO-3021, a novel antibody drug conjugate (ADC), by expanding the study to include Japan.
Read →
Unseen Challenges: The Quest for LGBTQIA+ Inclusivity in Patient Data
Pharma Pioneer
3 min read
Unseen Challenges: The Quest for LGBTQIA+ Inclusivity in Patient Data
22 May 2024
The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research.
Read →
PPTI Launches Phase I Trial for Zolmitriptan Microporation System in Migraine Treatment
Pharma Pioneer
2 min read
PPTI Launches Phase I Trial for Zolmitriptan Microporation System in Migraine Treatment
22 May 2024
San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.
Read →
Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years
Pharma Pioneer
2 min read
Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years
22 May 2024
AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.